Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Schizophrenia Therapeutics Market 2017-2021 - Key vendors are AstraZeneca, Eli Lilly, GlaxoSmithKline & Johnson & Johnson - Research and Markets

Research and Markets
Posted on: 01 Aug 17

The "Global Schizophrenia Therapeutics Market 2017-2021" report has been added to Research and Markets' offering.

The analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.

Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is Increase in use of LAI antipsychotic drugs. The global schizophrenia therapeutics market is witnessing an increase in the popularity of LAI antipsychotics, as they can attain higher efficacy in negative and cognitive predominant patients.

LAI antipsychotics are administered once every two or four weeks (depending on the specific drug). They improve patient compliance, which is important for long-term maintenance of therapeutic drugs, and are associated with both reduced hospitalization rates and reduced care costs.

One of the major drivers for this market is Increasing expenditure on prescription drugs.

The global schizophrenia therapeutics market witnessed a large shift in the clinical and economic role of prescription drugs because of the policy changes in the healthcare sector, availability of insurance coverage, introduction of behavioral healthcare techniques, and marketing strategies adopted by pharmaceutical companies to promote their products.

All these efforts have positively influenced the prescription value of antipsychotic drugs.

Key vendors

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson

Other prominent vendors

  • Alkermes
  • Bristol-Myers Squibb

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Schizophrenia: Disease overview

Part 06: Key clinical trials

Part 07: Market landscape

Part 08: Market segmentation based on drug-class

Part 09: Geographical segmentation

Part 10: Decision framework

Part 11: Drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

For more information about this report visit

View source version on

Business Wire

Last updated on: 01/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.